Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PTI's Remoxy: US FDA Panel To Weigh Intranasal Abuse Deterrence Against Oral Abuse Potential

Jun 25 2018

• By Sue Sutter

Related Content

Collegium Targets Remoxy ER Through Citizen Petition Process – Again

Apr 10 2018

Remoxy's Woes Stoke Criticism Of FDA's Review Of Abuse-Deterrent Opioids

Oct 01 2016

What's Missing In Intellipharmaceutics' Opioid Filing? FDA Panel Offers List

Jul 30 2017

Curtain Falls On Opana ER As Endo Agrees To US FDA Withdrawal Request

Jul 06 2017

Pain Therapeutics Confident It Has US Approval Pathway Set For Remoxy ER

Mar 21 2017

Related Companies

Cassava Sciences, Inc.

Purdue Pharma L.P.

Collegium Pharmaceutical, Inc.

Pfizer Inc.

Daiichi Sankyo Co., Ltd.

Inspirion Delivery Technologies LLC

Endo, Inc.

Intellipharmaceutics International Inc.

Zevra Therapeutics, Inc.

Additional Topics

United States Advisory Committees Drug Review Regulation Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.